Replies to post #217104 on Biotech Values

[DewDiligence]

GILD 4Q17 results/2018 guidance:

http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2330690

GILD’s guidance for 2018 sales from all products is $20-21B, down from $25.7B in 2017.

There is no guidance for 2018 HCV sales in the above PR, but there probably will be on today’s CC.